Screener
Kyverna Therapeutics, Inc. KYTX Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Available-for-sale marketable securities | 204,252 | 155,160 |
| Prepaid expenses and other current assets | 5,280 | 3,700 |
| Total current assets | 241,726 | 282,953 |
| Restricted cash | 551 | 551 |
| Property and equipment, net | 1,343 | 1,546 |
| Operating lease right-of-use assets | 8,192 | 3,568 |
| Finance lease right-of-use assets | 198 | 305 |
| Other non-current assets | 5,014 | 4,903 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s restricted cash?
- Kyverna Therapeutics, Inc. (KYTX) reported restricted cash of $551K in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s restricted cash changed year-over-year?
- Kyverna Therapeutics, Inc.'s restricted cash decreased by 1.1% year-over-year, from $557K to $551K.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s restricted cash?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s restricted cash has grown at a -1.2% compound annual growth rate (CAGR), from $565K to $551K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Kyverna Therapeutics, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude